Evidence map›Paper›PMID 29177437›Full record

SynthesisClinical infectious diseases : an official publication of the Infectious Diseases Society of America2018

Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis.

Anna Lena Lopez, Jacqueline Deen, Andrew S Azman, Francisco J Luquero, Suman Kanungo, Shanta Dutta, Lorenz von Seidlein, David A Sack

Open access · hybridAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Oral killed cholera vaccines for preventing cholera.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Comprehensive Review on the Use of Oral Cholera Vaccine (OCV) in Ethiopia: 2019 to 2023.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 4 countries.

Anna Lena LopezInstitute of Child Health and Human Development, National Institutes of Health, University of the Philippines, Manila.
Jacqueline DeenInstitute of Child Health and Human Development, National Institutes of Health, University of the Philippines, Manila.
Andrew S AzmanDepartment of Epidemiology, Johns Hopkins University, Baltimore, Maryland.
Francisco J LuqueroEpicentre, Paris, France.
Suman KanungoNational Institute of Cholera and Enteric Diseases, Beliaghata, Kolkata, West Bengal, India.
Shanta DuttaNational Institute of Cholera and Enteric Diseases, Beliaghata, Kolkata, West Bengal, India.
Lorenz von SeidleinDelivering Oral Vaccine Effectively, Department of International Health, Johns Hopkins University, Baltimore, Maryland.
David A SackDelivering Oral Vaccine Effectively, Department of International Health, Johns Hopkins University, Baltimore, Maryland.
Johns Hopkins University · USNational Institute of Cholera and Enteric Diseases · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In addition to improved water supply and sanitation, the 2-dose killed oral cholera vaccine (OCV) is an important tool for the prevention and control of cholera. We aimed to document the immunogenicity and protection (efficacy and effectiveness) conferred by a single OCV dose against cholera. The metaanalysis showed that an estimated 73% and 77% of individuals seroconverted to the Ogawa and Inaba serotypes, respectively, after an OCV first dose. The estimates of single-dose vaccine protection from available studies are 87% at 2 months decreasing to 33% at 2 years. Current immunologic and clinical data suggest that protection conferred by a single dose of killed OCV may be sufficient to reduce short-term risk in outbreaks or other high-risk settings, which may be especially useful when vaccine supply is limited. However, until more data suggest otherwise, a second dose should be given as soon as circumstances allow to ensure robust protection.

Indexed as

Immunogenicity, VaccineAdministration, OralCholeraCholera VaccinesDisease OutbreaksHumansImmunization ScheduleSeroconversionSerogroupVaccinationVaccine PotencyVaccines, InactivatedVibrio choleraeCholera VaccinesVaccines, Inactivated

Identifiers

PMID29177437
PMCPMC5982790
OpenAlexW2769976032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.